MindWalk Holdings Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $8.4M+54.9% YoYTTM through 31 Jan 2026
Net Income -$7.4MTTM through 31 Jan 2026
Free Cash Flow -$5.3MTTM through 31 Jan 2026
Margins
| Current | |
|---|---|
| Gross Margin | 59.3% |
| Operating Margin | -43.5% |
| Net Margin | -88.1% |
Returns
-82.0%ROE
-53.0%ROA
Balance Sheet Health
Debt / Equity0.24x
Current Ratio3.74x
Net Debt-$10.5Mnet cash position
Cash & Equivalents$14.2M
Quality Metrics
Piotroski F-Score2 / 9
FCF Margin-63.3%
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $24.5M
Diluted EPSFY2025: $-0.91
Dividend
No dividend
Capital Allocation
Capex Intensity9.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| United States | $2.6M | +100.0% | View detailsThe company expects continued growth in the U.S. market, supported by the establishment of biologics services operations in the Boston-Cambridge area. |
Financials converted at 1.3492 from CAD.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.